Founding Note: The Accessibility Crisis in Biological Medicine
Published March 2026
The Gap
In 2023, the FDA approved Casgevy — the first CRISPR-based gene therapy. It can cure sickle cell disease, a condition that causes excruciating pain crises and shortens lives by decades. The price: $2.2 million per patient.
Sickle cell disease affects approximately 100,000 people in the United States alone, and millions worldwide — predominantly in Sub-Saharan Africa, where healthcare spending per capita averages $83 per year.
The cure exists. The access doesn't.
This is not an isolated case. It is the defining pattern of modern biological medicine:
- Luxturna (gene therapy for inherited blindness): $850,000 per eye
- Zolgensma (gene therapy for spinal muscular atrophy): $2.1 million per dose
- CAR-T cell therapies for certain cancers: $400,000–$500,000 per treatment
- Average orphan drug annual cost: $32,000 per patient (vs. $2,115 for non-orphan drugs)
The science is delivering. The system is not.
Why This Matters Now
Three trends are converging to make this crisis both worse and more urgent:
1. The pipeline is accelerating. Gene therapies, cell therapies, RNA medicines, and CRISPR applications are moving from experimental to approved at unprecedented speed. The FDA's gene therapy pipeline alone has over 1,000 active INDs. Each approval will add another treatment that works but costs too much.
2. The diseases are getting rarer. As we move from common conditions to rare genetic diseases, each patient population shrinks. Pharma's unit economics — which depend on large patient pools to amortize R&D costs — break down. The patients who need these treatments most are the least commercially attractive.
3. Healthcare systems weren't built for this. Insurance models, hospital formularies, and national drug pricing frameworks were designed for mass-market pharmaceuticals — pills manufactured at scale for millions. They have no mechanism for a one-time, patient-specific genetic intervention that costs seven figures.
What BioSove Will Study
We've identified four problem clusters that collectively explain why the gap persists:
Treatment Economics — The cost structure of biological treatments is fundamentally different from traditional pharmaceuticals. A pill has near-zero marginal cost after R&D; a gene therapy is manufactured individually for each patient. We need to understand these cost structures in detail before we can propose alternatives.
Pipeline Compression — The 10–15 year development timeline for new treatments is not a law of nature. It's the result of specific regulatory, logistical, and institutional choices — some necessary, some legacy. We study where time is being wasted and what models could safely compress it.
Orphan Drug Viability — 7,000+ known rare diseases, treatments for fewer than 5% of them. The standard pharma business case fails when patient populations are measured in thousands, not millions. We analyze alternative models: platform trials that share infrastructure across diseases, gene therapy vectors that can be reprogrammed for different targets, and insurance models designed for high-cost one-time treatments.
System Adaptation — Precision medicine is personal by definition. But healthcare delivery is industrial by design. We study the structural adaptations needed — from hospital infrastructure to insurance frameworks to supply chain logistics — to deliver personalized biological treatments at scale.
Our Approach
BioSove is not a laboratory. We don't discover treatments. We study why existing treatments don't reach patients, and we publish our findings openly.
We believe that the accessibility crisis in biological medicine is not primarily a scientific problem — it is an economic, regulatory, and systemic one. And systemic problems require systemic research.
This is our first publication. More will follow.